Messenger RNA (mRNA) vaccines have been crucial to containing and controlling the ongoing Covid-19 pandemic. Advances in self-amplifying RNA technology promise to make them even more cost ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims ...

For example, they have characterized the transcriptome (mRNA, lncRNA, and miRNA) of aortas in an atherosclerosis mouse model, both during disease progression and after regression following treatment.

Hsieh's team has already showed that prostate cancer-associated mutations in the 5'UTR likely play an important role in prostate cancer. That left a question mark hanging over mRNA's other UTR.

This research indicates that Doxorubicin (Dox)-resistant TNBC cells exhibit increased glycolysis and ATP generation compared ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission ...

Combining AI-driven design with rapid, cell-free DNA synthesis, researchers are turning mRNA into a scalable solution for vaccines, cancer treatments, and personalized genetic therapies.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a new study.

Further analysis of the genes transcribed from the genomic island revealed that the 3'UTR of mRNA was processed to generate ManS, a novel small noncoding RNA of 80 nt in length.

Analysis of 3′UTR length variations. Shown are the length distribution of transcripts downregulated in ATS progression (C10 to C24, panels A) and treatment-induced regression (T10 vs. T24 ...

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers Provided by GlobeNewswire May 8, 2025 ...

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers ...